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ABSTRACT 
 
Microphthalmia and anophthalmia (MA) are severe developmental eye anomalies, many of 
which are likely to have an underlying genetic cause. More than 30 genes have been 
described, each of which is responsible for a small percentage of these anomalies. Amongst 
these, is the FOXE3 gene, which was initially described in individuals with dominantly 
inherited anterior segment dysgenesis and, subsequently, associated with recessively 
inherited primary aphakia, sclerocornea and microphthalmia. In this work, we describe 8 
individuals presenting with a MA phenotype. Among them, 7 are carrying biallelic recessive 
FOXE3 mutations and 2 of these have novel mutations: p.(Ala78Thr) and p.(Arg104Cys). The 
last of our patients is carrying in the heterozygous state the recessive p.(Arg90Leu) mutation 
in the FOXE3 gene. To further understand FOXE3 involvement in this wide spectrum of 
ocular anomalies with two different patterns of inheritance, we reviewed all individuals with 
ocular abnormalities described in the literature for which a FOXE3 mutation was identified. 
This review demonstrates that correlations exist between the mutation type, mode of 
inheritance and the phenotype severity. Furthermore, understanding the genetic basis of 
these conditions will contribute to overall understanding of eye development, improve the 
quality of care, genetic counseling and, in future, gene based therapies. 
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INTRODUCTION 
 
Eye development is driven by a complex network of molecular interactions, which depends 
on the precise dosage of numerous transcription factors acting via several signaling 
pathways. This process has been highly conserved throughout the evolution of vertebrates 
and any disruption to these events has the potential to generate an ocular anomaly. The 
different parts of the eye can be affected, resulting in anterior and/or posterior segment 
dysgenesis, as well as the entire globe, leading to microphthalmia or anophthalmia (MA). 
 
Anterior segment dysgeneses encompass a wide spectrum of developmental disorders 
affecting the cornea, iris and lens. They are generally associated with ~50% risk for glaucoma 
(1). Some specific diagnostic entities exist, such as Peters’ anomaly, which refers to the 
association of corneal opacity, defects in the posterior layers of the cornea and 
iridolenticulocorneal adhesions. 
 
MA malformations represent the most severe ocular anomalies and their prevalence is 
estimated to be between 0.6 and 3.2/10,000 infants (2). Anophthalmia refers to complete 
absence of the globe in the presence of ocular adnexa, whereas microphthalmia refers to a 
reduced total axial length of the globe that is at least 2 standard deviations below the mean 
for age. Microphthalmia is classified as simple, or complex, when associated with anterior 
and/or posterior segment dysgenesis, and graded depending on the degree of axial length 
reduction. Microphthalmia is often associated with coloboma which corresponds to the 
failure of closure of the optic fissure, extending inferonasally from the anterior to the 
posterior portion of the eye, during embryogenesis. Coloboma can affect the vision 
especially when located in the posterior segment of the eye, and encroaching on the visual 
axis or involving the optic nerve. 
 
The visual consequences of these ocular developmental defects are highly dependent on the 
associated ocular anomalies and unilateral or bilateral involvement. For example, Shah et al. 
(3) reported that 81% of microphthalmic eyes and 93% of microphthalmic eyes with 
coloboma were considered to have reduced vision. In a cohort of 98 patients with congenital 
corneal opacities (3/4 of whom had Peters’ anomaly), the best corrected visual acuity was 
 
 impaired in 81% of affected eyes of bilaterally affected patients (4). In addition, these ocular 
anomalies can be isolated or associated with extraocular anomalies (5). 
 
Although diverse, genetic origin appears to be the predominant cause of congenital ocular 
anomalies and recent advances in DNA sequencing technologies have significantly increased 
our knowledge of the underlying MA genes (6). The importance of their recognition and 
understanding is undeniable in terms of genetic counselling and prenatal diagnosis. 
Nevertheless, despite the identification of more than 30 genes in MA, mutations in each of 
these genes explain the symptoms in only a small percentage of patients. Indeed, overall 
the genetic cause is determined in around 30% of all MA patients, higher in severe MA 
cases (5- 7). The major gene still remains the SOX2 gene (MIM#184429), contributing to 
the cause in 10-15% of individuals usually with a severe MA phenotype, then OTX2 
(MIM#600037) (2- 5%), RAX (MIM#601881) (3%), PAX6 (MIM#607108) (2%) and FOXE3 
(MIM#601094) (2.5%) (6). The main genes involved in ASD are PAX6 (MIM#607108), 
CYP1B1 (MIM*601771) PITX2 (MIM*601542), FOXC1 (MIM*601090) and also FOXE3 
(MIM#601094) (1). 
 
Only a few studies have determined the mutation detection rate using whole exome 
sequencing (WES). Deml B et al. (8) screened 28 probands affected by microphthalmia, 
anophthalmia and coloboma with no mutations in SOX2 or FOXE3. They analyzed 83 genes 
involved in ocular development and identified mutations in 3 patients (11%). Weh E et al. (9) 
screened 27 patients affected by Peters’ anomaly by WES and found 6 causative mutations 
(22%). Thus, to date, WES approach did not demonstrate a much higher mutation detection 
rate in patients with ocular developmental defects compared with the targeting sequencing 
of the main known genes. This approach had mainly led to the identification of new genes in 
particular pedigrees (10-12). 
 
The FOXE3 gene encodes a transcription factor of 319 amino acids with a DNA-binding 
domain, the forkhead domain, located from amino acid 71 to 165 (13). FOXE3 is specifically 
expressed during lens development in human, mouse and zebrafish (14-16). It participates in 
lens vesicle formation and allows the maintenance of the lens cells in a proliferative state, 
thus preventing their early differentiation into lens fiber cells (14, 17). FOXE3 is known to be 
one of the master gene PAX6 targets (18) and, recently, Khan SY (19) demonstrated that 
FOXE3 acts through a downstream transcriptional target named DNAJB1, which has a crucial 
 
 role in the development and maintenance of lens transparency. 
 
Homozygous Foxe3 mutations were first identified in dyl/dyl mice displaying spontaneous 
microphthalmia associated with anterior segment abnormalities analogous to Peters’ 
anomaly and cataract in the human (14). The biallelic mutation identified in this dyl murine 
model is located in the Foxe3 forkhead domain and prevents the binding of the Foxe3 
protein to its DNA targets (13). In humans, mutations in FOXE3 were initially described in 
individuals with dominantly inherited anterior segment dysgeneses (13, 15). Subsequently, 
biallelic mutations were associated with primary congenital aphakia (20) and 
microphthalmia (21). In addition, Kuang SQ et al. (22) recently suggested that specific 
mutations located in a particular region of the forkhead domain (amino acids 137-164) may 
be responsible for familial forms of thoracic aorta dilatation (TAAD). 
 
Thus, the potential role of FOXE3 in a wide range of phenotypes with different patterns of 
inheritance prompted us to review all the individuals with ocular anomalies for which a 
FOXE3 mutation was identified in our laboratory and to compare this with published cases, 
to determine any genotype-phenotype correlation associated with mutations of this gene. 
 
METHODS 
 
This study was designed in compliance with the tenets of the Declaration of Helsinki and 
patient enrollment had approval by our local Ethics Committees (Cambridgeshire 1 Ethics 
Committee 04/Q0104/129 and CPP Sud-Ouest et Outre-Mer II). DNA from 8 new individuals 
presenting with a MA phenotype underwent Sanger sequencing of the coding regions and 
splice sites, combined with the investigation of exonic rearrangements (by semi-quantitative 
methods) of major genes responsible for non-syndromic MA. Of note, the SOX2 gene was 
first analyzed and then, if no mutation was identified, the analysis of the OTX2, PAX6, RAX 
and FOXE3 genes was performed. Segregation analysis of any identified mutation was 
performed in each family (parents and other affected family members when DNA was 
available). 
 
We then assembled all the clinical and genetic data available on individuals with ocular 
anomalies for which a FOXE3 mutation was identified and their relatives, from an exhaustive 
review of the literature using the PubMed database. Ocular phenotypes were classified into 
 
 two groups: (i) a so-called “severe” phenotype for microphthalmia (complex or not) and/or 
primary congenital aphakia and (ii) a so-called “mild” phenotype grouping anomalies of the 
anterior segment of the eye (such as posterior embryotoxon, Peters’ anomaly and congenital 
cataract). 
 
We categorized panocular involvement, such as microphthalmia and primary aphakia, as 
more severe in terms of developmental anomaly, compared to anomalies limited to the 
anterior segment, which were therefore considered as milder anomalies. 
 
After phenotypic categorization, we performed an analysis of the relationship between, (i) 
the type of mutation and the mode of transmission, (ii) the severity of the phenotype and 
the mode of transmission and (iii) the severity of the phenotype and the type of mutation. 
 
For studying the link between the mutation type and the severity of the phenotype, we used 
a logistic regression model. Since some subjects belonged to the same family, we also 
performed a logistic regression using the index cases alone. We present the marginal effects 
with their confidence intervals, i.e., the average predicted probabilities for each group. 
Concerning the link between the position of the truncating mutations and the severity of 
phenotype, we use a Fisher's exact test, as the conditions for using chi-square test or logistic 
regression were not met. Since some patients belonged to the same family, we also 
performed an analysis on the index cases only. 
 
P-values <0.05 were considered as significant (Wald test). Statistical analyses were 
performed with STATA release 14. 
 
RESULTS 
 
From our cohort and the published literature, this work includes a study of the phenotype 
and the genotype of 123 patients (38 index cases and 85 family members) with a total of 20 
different FOXE3 mutations (Fig.1). Of these, 102 patients have been identified with a biallelic 
mutation of FOXE3 (compound heterozygous or homozygous) and 21 patients with 
heterozygous mutations. 
 
 
 
 Nature and location of the FOXE3 mutations 
 
Mutations of various types have been reported: stop, frameshift, missense and no-stop. The 
position of these mutations is summarized in Figure 1. It appears that truncating mutations 
(stop or frameshift) are distributed throughout the gene, unlike missense mutations, which 
are all located in the forkhead domain. Mutations affecting the stop codon 
(p.(Ter320Argext*72), p.(Ter320Leuext*72) and p.(Ter320Serext*72)) are predicted to lead 
to a C-terminal extension of the protein, while preserving the entire FOXE3 sequence. Of 
note, a 3’end frameshift mutation (p.(Leu315AlafsTer117)) described here (Table 1) also 
results in a C-terminal extension with a conserved FOXE3 sequence (excepted for the 5 last 
amino acids of the protein) while all the other frameshift mutations described here are 
otherwise truncating. 
 
Monoallelic FOXE3 mutations (Table 1) 
 
Among the 21 patients described with a unique FOXE3 mutation, 17 have a no-stop 
mutation and 2 cases (an index case and a parent of that case) have the frameshift mutation 
p.(Leu315AlafsTer117), which similarly results in a C-terminal extension of the protein. Then, 
two individuals, one from our cohort and one described by Ormestad M. et al. (13) 
demonstrated the heterozygous p.(Arg90Leu) missense mutation that had previously always 
been associated with another FOXE3 pathogenic allele and associated with no phenotype in 
heterozygous subjects. Moreover, the individual from our cohort, who presented with 
bilateral anophthalmia, was carrying, in addition to the heterozygous p.(Arg90Leu) in the 
FOXE3 gene (inherited from her asymptomatic father), a de novo truncating mutation 
(p.(Ala198IlefsTer63)) in the OTX2 gene. The ocular phenotype observed in this patient is 
attributed to the OTX2 mutation rather than to the FOXE3 mutation (although a modifying 
effect of the p.(Arg90Leu) in FOXE3 cannot be completely excluded). As the p.(Arg90Leu) 
mutation is thought to be associated with recessive inheritance, these two latter patients 
were excluded from our genotype-phenotype correlation studies. 
 
Of the 19 patients analyzed, 18 showed isolated, but variable anterior segment anomalies. 
Only one patient reported in the literature (21) with a "dominant" mutation in the FOXE3 
gene displayed a severe ocular phenotype. This patient had the no-stop p.(Ter320Argext*72) 
mutation and bilateral complex microphthalmia whereas her affected relatives 
 
 demonstrated milder ocular phenotypes (anterior segment anomalies) (Table 1). 
 
Thus, the vast majority of patients with a dominant form (18/19, namely 95%) have isolated 
anterior segment dysgeneses, and all harbored a mutation leading to a C-terminal extension 
of the protein. 
 
Biallelic FOXE3 mutations (Table 2) 
 
A total of 102 patients with a biallelic FOXE3 mutation are reported here. Clinical and genetic 
data for all these patients and their relatives are summarized in Table 2. Among them, 7 are 
new patients from our cohort and 2 of these have novel mutations: c.232G>A (p.(Ala78Thr)) 
and c.310C>T (p.(Arg104Cys)). Eye picture of patient 1 from our cohort (Table 2) is shown in 
Figure 2. 
 
The c.232G>A mutation (rs377669670) is listed solely as heterozygote in the gnomAD 
database with an overall occurrence of 8 in 216582 alleles which includes 97090 alleles from 
European population. The low frequency of the p.(Ala78Thr) mutation in gnomAD and its 
segregation in two unrelated pedigrees reported here (patient 2 and family 2) strongly 
argues the pathogenic nature of this mutation in the homozygous (family 2) or compound 
heterozygous (patient 2) state. Moreover, this novel missense mutation affects a conserved 
amino acid located in the functional forkhead domain and is predicted pathogenic by in 
silico analyses (PolyPhen-2, MutationTaster, SNP&GO and SIFT software). 
 
The c.310C>T (p.(Arg104Cys)) is also listed solely as heterozygote in the gnomAD database 
with an overall occurrence of 1 in 244576 alleles which includes 110856 alleles from 
European population. This variant is therefore extremely rare. This novel missense mutation 
affects a conserved amino acid located in the functional forkhead domain and is predicted 
pathogenic by in silico analyses (PolyPhen-2, MutationTaster, SNP&GO and SIFT software). 
These data strongly argue the pathogenic nature of this variant. 
 
Thus, p.(Ala78Thr) and p.(Arg104Cys) are categorized as “likely pathogenic” variants 
according to the ACMG guidelines (23). These mutations were entered into the ClinVar 
database (respectively SCV000579340 and SCV000579341). 
 
 
 Out of all the individuals with biallelic mutations, 77% (79/102) presented with a severe 
ocular phenotype (eye growth anomalies with or without anterior segment dysgenesis, or 
primary congenital aphakia) and 23% (23/102) exhibited isolated anterior segment 
anomalies. The presence of an extraocular phenotype (Arnold-Chiari malformation, global 
developmental delay, autism, hypertrichosis, polycystic ovary syndrome, ventricular septal 
defect, renal pelvic dilatation and umbilical hernia) was only seen in individuals who also had 
severe ocular phenotypes. 
 
When considering the nature of the mutation, 37% (38/102) of the patients have 2 
truncating mutations while 60% (61/102) have 2 missense mutations in the FOXE3 gene. 
Three of them (3%) are compound heterozygote for a missense mutation and a truncating 
mutation (Table 3). It is worth noting that all relatives heterozygous for these mutations are 
asymptomatic, suggesting a recessive mode of inheritance. 
 
The analysis of the mutation type and the phenotype severity in the recessive forms (Table 
3) shows that 90% of patients with at least one truncating mutation (37/41) displayed a 
severe ocular phenotype, sometimes (22%) associated with extraocular features, while 69% 
(42/61) with biallelic missense mutations had a severe ocular phenotype which was always 
isolated. In addition, only 4 of the 23 (17%) patients with anterior segment dysgenesis have 
2 truncating mutations while this phenotype was observed in 19 of the 61 patients (31%) 
with 2 missense mutations. 
 
Statistical analyses of the data above (Table 4) show that the FOXE3 mutation type has a 
strong influence on the severity of the ocular and extraocular phenotype (p<0.05). Indeed, 
when considering all the patients, the average predicted probability of them presenting with 
a severe ocular phenotype was 88.2% (95% CI=[77.4;99.1]) for patients with at least one 
truncating mutation and 68.9% (95% CI=[57.2;80.5]) for patients with 2 missense mutations 
(p=0.016). When we performed the same analysis on index cases alone (32 families) in order 
to see if we could separate the mutation effect and the family effect, we observed exactly 
the same tendency, but the difference between the groups was no longer statistically 
significant (p=0.208). Indeed, the rarity of the disease meant that there was an insufficient 
number of index cases to analyze. 
 
 
 
 Thus, truncating FOXE3 mutations are more frequently associated with a severe phenotype 
than missense mutations. In addition to the severe ocular phenotype, truncating mutations 
are associated with a phenotype that includes extraocular features in one quarter of 
patients. 
 
Furthermore, given that truncating mutations, unlike missense mutations, are distributed 
throughout the FOXE3 gene, we studied a possible correlation between their position in 
relation to the forkhead domain and the phenotypic severity. No significantly statistical 
correlation could be established (Table 5). 
 
DISCUSSION 
 
We report here 8 new individuals with mutations in the FOXE3 gene, a gene that has been 
involved in a wide spectrum of ocular anomalies with different patterns of inheritance. Thus, 
in order to bring appropriate genetic counselling to these families, we reviewed all the 
ocular phenotype of individuals with FOXE3 mutations reported in the literature, to 
determine if genotype-phenotype correlations could be drawn. 
 
This meta-analysis demonstrates that recessive cases are more frequent than dominant 
(84% versus 16%) and are associated with a more severe phenotype (77% versus 5%). 
Inferences can be drawn from the nature of the mutation. Truncating mutations are 
recessively inherited and generally lead to a severe phenotype, both ocular and extraocular 
features (Table 2). Missense mutations are also recessively inherited and associated with an 
isolated ocular phenotype, which can be mild in one third of cases. Dominant forms are 
associated with the presence of mutations leading to a C-terminal extension of the protein 
and responsible for an isolated and relatively mild ocular phenotype. 
 
Finally, association of truncating and missense mutations with recessive inheritance in 
contrast to the “elongating” mutations that appear exclusively dominant suggests that 
pathogenic effects are driven by distinct mechanisms. Recent work (24) has attempted to 
explore further the mechanisms underlying the possible relationship between the nature 
and position of the FOXE3 mutations, the mode of transmission and the severity of the 
phenotype. Their in vitro functional studies showed that the recessive mutations tested (2 
missense mutations affecting the forkhead domain and 2 frameshift mutations one before 
 
 and one after the forkhead domain) led to reduced ability to bind DNA and activate 
transcription. A “loss-of-function” mechanism therefore seemed probable for these 
“recessive” truncating and missense mutations. 
 
For the “dominant” mutations, a dominant negative effect was initially proposed wherein 
FOXE3 mutants would bind to their DNA target without transactivation capacity and thus 
prevent the action of the wild-type FOXE3 proteins. Islam L. et al. (24) investigated this 
hypothesis by testing two "dominant" mutations (1 no-stop and 1 frameshift leading to a C- 
terminal extension). However, they showed that, although the mutant proteins retained 
their DNA binding capacity with a reduction in their transactivation capabilities, they did not 
interfere with the wild-type protein after in vitro modelling of the heterozygous state. They 
suggested rather a gain-of-function mechanism for these “elongating” mutations. 
 
In this situation, the mutant FOXE3 protein could exhibit a new property that would affect 
the development of the eye; the presence of the wild-type allele would then presumably 
allow the synthesis of a functional protein, explaining why the phenotype associated with 
the "dominant" mutations is less severe. Furthermore, this hypothesis could explain why 
heterozygous carriers of recessive genetic mutations are not symptomatic. Thus, the 
different modes of transmission observed for these mutations do not seem to be linked to a 
simple gene dosage effect, but rather to a difference in the mechanisms involved, related to 
the nature and position of the mutations in FOXE3. 
 
Phenotypic variability and mode of inheritance may be compounded by another level of 
complexity, involving the position of the missense mutations. As mentioned above, 
mutations in the FOXE3 gene have recently been implicated in dominant familial forms of 
thoracic aorta dilatation (TAAD) without ocular abnormalities (22). These mutations are all 
heterozygous missense mutations located at the 3' end of the forkhead domain (Fig.1). A 
mechanism different from that observed with mutations responsible for an ocular 
phenotype (depending mainly on the position of these missense mutations) has been 
suggested (22). Thus, it has been hypothesized that the missense mutations position in the 
forkhead  domain  could  have  an  impact  on  both  the  mode  of  transmission  and  the 
phenotype: a recessive ocular versus a dominant vascular phenotype. However, we can 
see that several individuals (7 in total) reported by Saboo US et al. (25) and in our study 
(mother of patient 5, Table 2) were heterozygous for the missense mutation p.(Gly158Arg) 
 
 located in the 3’ region of the forkhead domain (Fig.1), but did not demonstrate any aortic 
dilatation. 
 
In conclusion, this review demonstrates the presence of genotype-phenotype correlations 
for FOXE3 mutations in congenital ocular abnormalities. These correlations will assist both in 
interpreting the molecular data of FOXE3 analysis when the phenotype is known, and in 
predicting phenotype and mode of inheritance when knowing the genotype in a family. 
Moreover, these correlations lay the foundations for exploring in more detail the effects of 
potential modifying factors that could influence the ocular phenotype, improving our 
understanding of eye morphogenesis and ocular genetic diseases in general. 
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gnomAD: http://gnomad.broadinstitute.org 
MutationTaster: http://www.mutationtaster.org 
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LEGENDS 
 
Figure 1: Schematic representation of the FOXE3 protein. The grey part corresponds to the forkhead domain (amino acids 71 
to 165). The upper section shows the position of the recessive (biallelic) mutations. The lower section shows the position of 
the dominant (monoallelic) mutations. The truncating mutations are shown in red, the missense mutations in green and the 
no-stop mutations in blue. The red box indicates the 4 missense mutations described by Kuang SQ et al. in the dominant 
forms of aortic dilation (TAAD) without associated ocular phenotype (22). For each mutation, allele frequency from the 
gnomAD database is given in parentheses (a dash is indicated when unknown). 
 
 
 
Figure 2: Eye picture of patient 1 from our cohort (Table 2) displaying normal external appearance of 
pseudophakic right eye, and left microphthalmia with sclerocornea and right Peters’ anomaly. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 Table 1: Summary of monoallelic FOXE3 mutations and associated phenotypes. 
 
Table 2: Summary of biallelic FOXE3 mutations and related phenotypes. 
ACM = Arnold-Chiari malformation; ASD = anterior segment dysgenesis; ICA = irido-corneal adhesions; GDD = 
global developmental delay; ODC = optic disc coloboma; PCOS = polycystic ovary syndrome; RD = retinal 
detachment; VSD = ventricular septal defect. In bold, individuals with a missense mutation on one allele and a 
truncating mutation on the other one. *Sclerocornea can present as total opacification of the cornea 
(sclerocornea totalis) or as a peripheral corneal opacification (scleralization) leaving a central clear corneal 
area. For these patients, the clinical description was corneal opacity without any additional information. 
**Abnormal folds of the retina in which the retinal lamination is disturbed (20). ***Mild cortical and blue dot 
lens opacities visible on dilated eye examination. 
 
Table 3: Phenotype of patients in relation to FOXE3 mutations in the recessive forms. 
 
Table 4: Statistical analyses of the mutation type and the phenotype severity correlations in the recessive forms. Mg*: 
Margins, i.e. average predicted probabilities of having a severe phenotype 
 
Table 5: Statistical analyses of the correlation between the position of truncating mutations in 
relation to the forkhead domain (before/after) and the phenotype severity. 
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Table 1: Summary of monoallelic FOXE3 mutations and associated phenotypes. 
 
Publication Patients Monoallelic mutations Ocular phenotype Extraocular 
phenotype 
Father Mother 
Doucette L. 
2011 11 patients 
c.[959G>T];[=] 
p.[(Ter320Leuext*72)];[=] ASD 
   
Bremond- 
Gignac D. 
2010 
 
Patient 1 
 
c.[959G>C];[=] 
p.[(Ter320Serext*72)];[=] 
 
Congenital cataract 
 Genetic data not 
available 
asymptomatic 
Genetic data not 
available 
asymptomatic 
 
Iseri SU. 
2009 
 
Family 3 
(5 patients) 
 
c.[958T>C];[=] 
p.[(Ter320Argext*72)];[=] 
1/5 with bilateral 
complex 
microphthalmia 
4/5 with ASD or early 
onset cataract 
   
Ormestad 
M. 2002 
 
Patient 1 c.[269G>T];[=] p.[(Arg90Leu)];[=] 
 
Peters’ anomaly 
   
 
Semina EV. 
2001 
 
Patient 1 
c.[942dup];[=] 
p.[(Leu315AlafsTer117)];[=] 
Cataract, 
posterior 
embryotoxon, 
myopia 
 Genetic and 
clinical data not 
available 
c.[942dup];[=] 
Cataract, posterior 
embryotoxon 
  
Table 2: Summary of biallelic FOXE3 mutations and related phenotypes 
 
 
Publication Patients Biallelic mutations Ocular phenotype Extraocular 
phenotype 
Father Mother 
 
Chen J. 
2017 
 
Family 1 
(5 patients) 
 
c.[307G>A];[307G>A] 
p.[(Glu103Lys)];[(Glu103Lys)] 
 
Congenital cataract 
  
c.[307G>A];[=] 
asymptomatic 
 
c.[307G>A];[=] 
asymptomatic 
 
Saboo US. 
2016 
 
Family 1 
(3 patients) 
 
c.[472G>C];[472G>C] 
p.[(Gly158Arg)];[(Gly158Arg)] 
Bilateral 
microphthalmia with 
aphakia, sclerocornea 
and anterior 
staphyloma 
  
c.[472G>C];[=] 
asymptomatic 
 
c.[472G>C];[=] 
asymptomatic 
 
 
 
 
 
Ullah E. 
2016 
Family 
MA115 
(2 patients) 
 
c.[21_24del];[21_24del] 
p.[(Met7IlefsTer216)];[(Met7Ilefs 
Ter216)] 
Bilateral complex 
microphthalmia with 
aphakia and corneal 
opacity* 
  
c.[21_24del];[=] 
asymptomatic 
 
c.[21_24del];[=] 
asymptomatic 
Family 
MA119 
(3 patients) 
 
c.[21_24del];[21_24del] 
p.[(Met7IlefsTer216)];[(Met7Ilefs 
Ter216)] 
Bilateral complex 
microphthalmia with 
aphakia and corneal 
opacity* 
 Genetic data 
not available. 
asymptomatic 
c.[21_24del];[=] 
asymptomatic 
Family 
MA143 
(3 patients) 
 
c.[289A>G];[289A>G] 
p.[(Ile97Val)];[(Ile97Val)] 
Bilateral complex 
microphthalmia with 
aphakia and corneal 
opacity* 
  
c.[289A>G];[=] 
asymptomatic 
 
c.[289A>G];[=] 
asymptomatic 
 
 
 
Khan YS. 
2016 
Family 
PKCC139 
(4 patients) 
c.[720C>A];[ 720C>A] 
p.[(Cys240Ter)];[(Cys240Ter)] 
Peters’ anomaly 
glaucoma 
 c.[720C>A];[=] 
asymptomatic 
c.[720C>A];[=] 
asymptomatic 
Family 
PKCC009 
(5 patients) 
c.[351C>G];[351C>G] 
p.[(Asn117Lys)];[(Asn117Lys)] 
 
Congenital cataract 
 c.[351C>G];[=] 
asymptomatic 
c.[351C>G];[=] 
asymptomatic 
Family 
PKCC039 
(7 patients) 
c.[307G>A];[307G>A] 
p.[(Glu103Lys)];[(Glu103Lys)] 
 
Congenital cataract 
 c.[307G>A];[=] 
asymptomatic 
c.[307G>A];[=] 
asymptomatic 
 
 
 
 
 
Islam L. 
2015 
 
Patient 1 
 
c.[358C>G];[(358C>G)] 
p.[(Arg120Gly)];[(Arg120Gly)] 
Bilateral primary 
aphakia, corneal 
opacity*, ICA, RD 
microphthalmia, and 
glaucoma 
  
Genetic data 
not available. 
Asymptomatic 
 
c.[358C>G];[=] 
asymptomatic 
 
 
 
Patient 2 
 
c.[21_24del];[21_24del] 
p.[(Met7IlefsTer216)];[(Met7Ilefs 
Ter216)] 
Bilateral primary 
aphakia with 
congenital corneal 
opacity*, ICA, RD 
glaucoma, corneal 
perforation 
  
 
c.[21_24del];[=] 
asymptomatic 
 
 
c.[21_24del];[=] 
asymptomatic 
 
 
Patient 3 
c.[269G>T];[705delC] 
p.[(Arg90Leu)];[(Glu236SerfsTer 
71)] 
Bilateral primary 
aphakia with 
congenital corneal 
opacity* and glaucoma 
  
c.[705delC];[=] 
asymptomatic 
 
c.[269G>T];[=] 
asymptomatic 
Garcia- 
Montalvo 
AI. 2014 
 
Patient 1 
c.[292T>C];[(292T>C)] 
p.[(Tyr98His)];[(Tyr98His)] 
Bilateral complex 
microphthalmia with 
sclerocornea 
 Genetic and 
clinical data not 
available 
Genetic and 
clinical data not 
available 
 
Chassaing 
N. 
2014 
 
Patient 28 
c.[685_686insTCCGGAGC];[(685_6 
86insTCCGGAGC)] 
p.[(Ala230ArgfsTer3)];[(Ala230Arg 
fsTer3)] 
Bilateral complex 
microphthalmia with 
sclerocornea 
GDD Genetic data not 
available 
asymptomatic 
c.[685_686insTC 
CGGAGC];[=] 
asymptomatic 
Family 1 
(Patient 29 
and sibling) 
c.[720C>A];[(720C>A)] 
p.[(Cys240Ter)];[(Cys240Ter)] 
Bilateral complex 
microphthalmia with 
sclerocornea 
 
PCOS 
Genetic data not 
available 
asymptomatic 
Genetic data not 
available 
asymptomatic 
Pantoja- 
Melendez C. 
2013 
 
17 patients 
c.[292T>C];[292T>C] 
p.[(Tyr98His)];[(Tyr98His)] 
Bilateral complex 
microphthalmia, 
sclerocornea, aphakia, 
ODC 
 c.[292T>C];[=] 
asymptomatic 
c.[292T>C];[=] 
asymptomatic 
  
Publication Patients Biallelic mutations Ocular phenotype Extraocular 
phenotype 
Father Mother 
Lopez 
Jimenez N. 
2011 
 
Patient 1 
c.[720C>A];[(720C>A)] 
p.[(Cys240Ter)];[(Cys240Ter)] 
Bilateral 
microphthalmia ACM 
Genetic and 
clinical data not 
available 
Genetic and 
clinical data not 
available 
 
 
 
 
 
 
 
 
 
 
 
 
Reis ML. 
2010 
 
Patient 1 
 
 
 
Patient 2 
 
 
 
 
 
Patient 3 
 
 
 
 
Patient 4 
c.[244A>G];[705delC] 
p.[(Met82Val)];[(Glu236SfsTer71)] 
 
 
c.[557delT];[557delT] 
p.[(Phe186SerfsTer38)];[(Phe186Serfs 
Ter38)] 
 
 
 
c.[720C>A];[(720C>A)] 
p.[(Cys240Ter)];[(Cys240Ter)] 
 
 
 
c.[720C>A];[720C>A] 
p.[(Cys240Ter)];[(Cys240Ter)] 
Bilateral severe 
microphthalmia 
sclerocornea 
Bilateral 
microphthalmia, 
sclerocornea, aphakia, 
dysplastic irides, 
probable glaucoma 
Bilateral 
microphthalmia, 
aphakia, corneal 
opacity*, glaucoma, 
possible optic disc 
drusen and right ODC 
Bilateral 
microphthalmia, 
sclerocornea, 
coloboma, corneal 
ectasia and glaucoma 
Bilateral 
Renal 
pelvis 
dilatation 
 
 
 
 
 
 
 
Autism 
GDD 
 
 
 
ACM, 
Umbilical 
hernia 
c.[705delC];[=] 
asymptomatic 
 
 
c.[557delT];[=] 
asymptomatic 
 
 
 
Genetic data not 
available 
asymptomatic 
 
 
 
c.[720C>A];[=] 
asymptomatic 
c.[244A>G];[=] 
asymptomatic 
 
 
c.[557delT];[=] 
asymptomatic 
 
 
 
Genetic data not 
available 
asymptomatic 
 
 
 
c.[720C>A];[=] 
asymptomatic 
Patient 5 c.[720C>A];[720C>A] 
p.[(Cys240Ter)];[(Cys240Ter)] 
microphthalmia, 
sclerocornea, corneal 
ectasia and glaucoma 
Hyper 
-trichosis 
c.[720C>A];[=] 
asymptomatic 
c.[720C>A];[=] 
asymptomatic 
Anjum I. 
2010 
 
Ali M. 
2010 
 
 
 
 
 
 
Iseri SU. 
2009 
 
 
 
 
 
Valleix S. 
2006 
Family 1 
(5 patients) 
Family 
MEP54 
(7 patients) 
Mexican 
family 
(9 patients) 
 
Family 1 
(6 patients) 
 
 
Family 2 
(3 patients) 
 
 
Siblings 
(3 patients) 
c.[720C>A];[ 720C>A] 
p.[(Cys240Ter)];[(Cys240Ter)] 
 
c.[292T>C];[292T>C] 
p.[(Tyr98His)];[(Tyr98His)] 
 
c.[720C>A];[720C>A] 
p.[(Cys240Ter)];[(Cys240Ter)] 
 
 
c.[244A>G];[244A>G] 
p.[(Met82Val)];[(Met82Val)] 
 
c.[21_24del];[21_24del] 
p.[(Met7IlefsTer216)];[(Met7Ilefs 
Ter216)] 
 
c.[720C>A];[720C>A] 
p.[(Cys240Ter)];[(Cys240Ter)] 
Bilateral primary 
aphakia 
 
Microphthalmia, 
aphakia, sclerocornea 
Microphthalmia, 
aphakia, sclerocornea 
and ODC 
4/6 with complex 
microphthalmia and/or 
primary aphakia with 
sclerocornea 
2/6: ASD and glaucoma 
Complex 
microphthalmia, 
bilateral primary 
aphakia, sclerocornea 
Bilateral primary 
aphakia, aniridia, 
microphthalmia and 
retinal dysplasia** 
Left microphthalmia 
c.[720C>A];[=] 
asymptomatic 
 
Genetic data not 
available 
asymptomatic 
c.[720C>A];[=] 
asymptomatic 
 
 
c.[244A>G];[=] 
asymptomatic 
 
 
 
GDD c.[21_24del];[=] 
asymptomatic 
 
 
c.[720C>A];[=] 
asymptomatic 
c.[720C>A];[=] 
asymptomatic 
 
Genetic data not 
available 
asymptomatic 
c.[720C>A];[=] 
asymptomatic 
 
 
c.[244A>G];[=] 
asymptomatic 
 
 
 
c.[21_24del];[=] 
asymptomatic 
 
 
c.[720C>A];[=] 
asymptomatic 
 
 
 
 
 
 
 
Patients in 
Patient 1 c.[244A>G];[269G>T] 
p.[(Met82Val)];[(Arg90Leu)] 
 
Patient 2 c.[310C>T];[232G>A] 
p.[(Arg104Cys)];[(Ala78Thr)] 
 
c.[345G>A];[472G>C] 
with sclerocornea and 
right Peters’ anomaly 
Unilateral 
microphthalmia with 
bilateral sclerocornea 
Bilateral complex 
 
 
 
 
 
 
 
GDD 
c.[244A>G];[=] 
asymptomatic 
 
c.[310C>T];[=] 
asymptomatic 
 
c.[345G>A];[=] 
clinical data not 
c.[269G>T];[=] 
asymptomatic*** 
 
c.[232G>A];[=] 
asymptomatic 
 
c.[472G>C];[=] 
clinical data not 
this study Patient 3 
 
Family 1 
(2 sisters) 
 
Family 2 
(2 sisters) 
p.[(Trp115Ter)];[(Gly158Arg)] 
 
 
c.[244A>G];[244A>G] 
p.[(Met82Val)];[(Met82Val)] 
 
c.[ 232G>A];[232G>A] 
p.[(Ala78Thr)];[(Ala78Thr)] 
microphthalmia with 
sclerocornea 
Bilateral complex 
microphthalmia with 
sclerocornea 
Bilateral complex 
microphthalmia with 
Peters’ anomaly 
VSD available 
 
c.[244A>G];[=] 
asymptomatic 
 
c.[232G>A];[=] 
asymptomatic 
available 
 
c.[244A>G];[=] 
asymptomatic 
 
c.[232G>A];[=] 
asymptomatic 
  
Table 3: Phenotype of patients in relation to FOXE3 mutations in the recessive forms 
 
 
 
 
 
Mutation type 
 
Mild 
ocular 
phenotype 
 
Severe 
ocular 
phenotype 
Severe 
ocular phenotype with 
extraocular features 
 
 
 
Total 
 
 
 
Distribution 
2 missense 19 42 0 61 60% 
1 missense + 1 truncating 0 1 2 3 3% 
2 truncating 4 27 7 38 37% 
Total 23 70 9 102  
Distribution 23% 69% 8%  
  
Table 4: Statistical analyses of the mutation type and the phenotype severity correlations in the 
recessive forms 
 
 
 
 
 
Population sizes 
Probability of having a severe 
phenotype 
(Logistic regression) 
 N n % n Mg* 95% CI p-value 
 
All patients 
 
102 
      
No truncating  61 59.8 42 68.9 57.2 ; 80.5 0.016 
At least one truncating  41 40.2 37 88.2 77.4 ; 99.1  
Index cases only 32       
No truncating  14 43.8 11 78.6 57.1 ; 1.00 0.208 
At least one truncating  18 56.2 17 94.4 83.9 ; 1.00  
 Table 5: Statistical analyses of the correlation between the position of truncating mutations in 
relation to the forkhead domain and the phenotype severity 
 
Population sizes 
N n % 
Probability of being 
severe (Exact test) 
n % p-value 
All patients  41      
 Before  10 24.4 10 100.0 0.556 
 After  31 75.6 27 87.1  
Index cases only  18      
 Before  5 27.8 5 100.0 1.000 
 After  13 72.2 12 92.3  
 
 
